Literature DB >> 3125032

Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function.

D Höffler1, P Koeppe.   

Abstract

Ten healthy volunteers and 20 patients suffering from chronic renal failure of varying severity received a single dose of ofloxacin 200mg orally. Ofloxacin concentrations were determined in blood and urine, and kidney function was assessed by measuring glomerular filtration rate (GFR) and plasma creatinine concentrations. The results show that there is a relationship between the area under the concentration-time curve for ofloxacin and both GFR and plasma creatinine concentration. On the basis of these results, a means of determining suitable dosage reduction factors in patients with renal impairment is presented. It is anticipated that appropriate reductions in the amount of ofloxacin administered to such patients will reduce the risk of central nervous system side effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3125032     DOI: 10.2165/00003495-198700341-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Safety of ofloxacin--adverse drug reactions reported during phase-II studies in Europe and in Japan.

Authors:  R Blomer; K Bruch; H Krauss; W Wacheck
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  [Recent nephrologic examination methods. A critical review].

Authors:  D Höffler; P Fiegel
Journal:  Dtsch Med Wochenschr       Date:  1972-06-09       Impact factor: 0.628

3.  [Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe].

Authors:  R Blomer; K Bruch; R N Zahlten
Journal:  Infection       Date:  1986       Impact factor: 3.553

4.  [Ofloxacin versus pipemidic acid and co-trimoxazole].

Authors:  R Wittenberger
Journal:  Infection       Date:  1986       Impact factor: 3.553

5.  [New oral quinolone compounds in chronic bronchitis].

Authors:  B I Davies; F P Maesen; J P Teengs; C Baur
Journal:  Infection       Date:  1986       Impact factor: 3.553

  5 in total
  8 in total

1.  Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.

Authors:  D Kampf; K Borner; A Pustelnik
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Authors:  I D Rosca; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

Review 3.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

4.  Effect of renal impairment on distribution of ofloxacin.

Authors:  A Sanchez Navarro; J Martinez Lanao; M M Sanchez Recio; A Domínguez-Gil Hurlé; J M Tabernero Romo; J C Gomez Sanchez; M M Terreiro Delgado
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 5.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 7.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 8.  Ofloxacin pharmacokinetics in chronic renal failure and dialysis.

Authors:  N Lameire; B Rosenkranz; V Malerczyk; K H Lehr; N Veys; S Ringoir
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.